Cytosorbents (CTSO) Expected to Announce Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is expected to release its earnings data after the market closes on Thursday, March 6th. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Cytosorbents Trading Down 2.8 %

Cytosorbents stock opened at $1.03 on Tuesday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The stock’s 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.05. The firm has a market cap of $56.32 million, a PE ratio of -2.86 and a beta of 0.61.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. StockNews.com assumed coverage on Cytosorbents in a research report on Sunday. They set a “hold” rating on the stock. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Finally, HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.